Advances in Merkel cell carcinoma from a pathologist's perspective

Area of Science:

• Oncology
• Dermatology
• Molecular Pathology

Background:

• Merkel cell carcinoma (MCC) presents a significant challenge due to its aggressive nature and poor prognosis with advanced disease.
• Traditional treatments like surgery and radiotherapy are effective for local disease, but metastatic MCC has historically responded poorly to cytotoxic chemotherapy.
• Current guidelines often recommend clinical trials over standard chemotherapy for advanced MCC.

Purpose of the Study:

• To provide an updated overview of Merkel cell carcinoma diagnosis, staging, and management.
• To highlight recent advancements in understanding the molecular pathogenesis of MCC.
• To discuss promising novel therapeutic strategies for MCC.

Main Methods:

• Review of current literature on Merkel cell carcinoma.
• Analysis of recent findings in molecular biology and tumor pathogenesis.
• Synthesis of emerging therapeutic approaches and experimental treatments.

Main Results:

• MCC is a rare but aggressive neuroendocrine carcinoma of the skin.
• Advanced MCC has a poor prognosis, with limited efficacy of traditional chemotherapy.
• Emerging therapies targeting MCC's molecular pathways show significant promise.

Conclusions:

• Understanding MCC's molecular basis is crucial for developing effective treatments.
• Novel therapeutic strategies offer new hope for patients with advanced Merkel cell carcinoma.
• Continued research into MCC pathogenesis and treatment is essential.